Factors associated with response to calcineurin inhibitors in myasthenia gravis

Yuriko Nagane, Shigeaki Suzuki, Norihiro Suzuki, Kimiaki Utsugisawa

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The objective was to assess which clinical factors of patients with myasthenia gravis (MG) are associated with responsiveness to calcineurin inhibitors (CNIs, cyclosporine and tacrolimus). We retrospectively analyzed the 6-month effects of CNIs in 62 MG patients. We excluded the influence of other immune treatments and determined factors associated with response to CNIs. The frequency of patients who achieved neither a ≥3-point reduction in quantitative MG score nor a ≥25% reduction in daily dose of prednisolone (poor responders) reached 35.5% (22/62) and 64.5% (40/62), respectively, compared with patients who achieved at least one of these improvements (responders). Neither dose nor blood concentration of CNIs differed between groups. Multivariate logistic regression analysis revealed time since onset of disease [odds ratio (OR) = 0.85, P = 0.005] and presence of thymoma (OR = 5.56, P = 0.05) as clinical factors that predict response to CNIs. As for MG-related autoantibody status, an autoantibody against a voltage-gated potassium channel, Kv1.4, was associated with response (OR = 9.01, P = 0.04) and showed a correlation with the presence of thymoma (P < 0.01). In MG, the early stages of disease and thymoma-associated MG are responsive to treatment with CNIs.

Original languageEnglish
Pages (from-to)212-218
Number of pages7
JournalMuscle and Nerve
Volume41
Issue number2
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Myasthenia Gravis
Thymoma
Odds Ratio
Autoantibodies
Voltage-Gated Potassium Channels
Tacrolimus
Prednisolone
Cyclosporine
Calcineurin Inhibitors
Logistic Models
Regression Analysis
Therapeutics

Keywords

  • Calcineurin inhibitors
  • Logistic regression analysis
  • Myasthenia gravis
  • Odds ratio
  • Response

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Factors associated with response to calcineurin inhibitors in myasthenia gravis. / Nagane, Yuriko; Suzuki, Shigeaki; Suzuki, Norihiro; Utsugisawa, Kimiaki.

In: Muscle and Nerve, Vol. 41, No. 2, 02.2010, p. 212-218.

Research output: Contribution to journalArticle

Nagane, Yuriko ; Suzuki, Shigeaki ; Suzuki, Norihiro ; Utsugisawa, Kimiaki. / Factors associated with response to calcineurin inhibitors in myasthenia gravis. In: Muscle and Nerve. 2010 ; Vol. 41, No. 2. pp. 212-218.
@article{dc6e84e2974941819753abba35565529,
title = "Factors associated with response to calcineurin inhibitors in myasthenia gravis",
abstract = "The objective was to assess which clinical factors of patients with myasthenia gravis (MG) are associated with responsiveness to calcineurin inhibitors (CNIs, cyclosporine and tacrolimus). We retrospectively analyzed the 6-month effects of CNIs in 62 MG patients. We excluded the influence of other immune treatments and determined factors associated with response to CNIs. The frequency of patients who achieved neither a ≥3-point reduction in quantitative MG score nor a ≥25{\%} reduction in daily dose of prednisolone (poor responders) reached 35.5{\%} (22/62) and 64.5{\%} (40/62), respectively, compared with patients who achieved at least one of these improvements (responders). Neither dose nor blood concentration of CNIs differed between groups. Multivariate logistic regression analysis revealed time since onset of disease [odds ratio (OR) = 0.85, P = 0.005] and presence of thymoma (OR = 5.56, P = 0.05) as clinical factors that predict response to CNIs. As for MG-related autoantibody status, an autoantibody against a voltage-gated potassium channel, Kv1.4, was associated with response (OR = 9.01, P = 0.04) and showed a correlation with the presence of thymoma (P < 0.01). In MG, the early stages of disease and thymoma-associated MG are responsive to treatment with CNIs.",
keywords = "Calcineurin inhibitors, Logistic regression analysis, Myasthenia gravis, Odds ratio, Response",
author = "Yuriko Nagane and Shigeaki Suzuki and Norihiro Suzuki and Kimiaki Utsugisawa",
year = "2010",
month = "2",
doi = "10.1002/mus.21462",
language = "English",
volume = "41",
pages = "212--218",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Factors associated with response to calcineurin inhibitors in myasthenia gravis

AU - Nagane, Yuriko

AU - Suzuki, Shigeaki

AU - Suzuki, Norihiro

AU - Utsugisawa, Kimiaki

PY - 2010/2

Y1 - 2010/2

N2 - The objective was to assess which clinical factors of patients with myasthenia gravis (MG) are associated with responsiveness to calcineurin inhibitors (CNIs, cyclosporine and tacrolimus). We retrospectively analyzed the 6-month effects of CNIs in 62 MG patients. We excluded the influence of other immune treatments and determined factors associated with response to CNIs. The frequency of patients who achieved neither a ≥3-point reduction in quantitative MG score nor a ≥25% reduction in daily dose of prednisolone (poor responders) reached 35.5% (22/62) and 64.5% (40/62), respectively, compared with patients who achieved at least one of these improvements (responders). Neither dose nor blood concentration of CNIs differed between groups. Multivariate logistic regression analysis revealed time since onset of disease [odds ratio (OR) = 0.85, P = 0.005] and presence of thymoma (OR = 5.56, P = 0.05) as clinical factors that predict response to CNIs. As for MG-related autoantibody status, an autoantibody against a voltage-gated potassium channel, Kv1.4, was associated with response (OR = 9.01, P = 0.04) and showed a correlation with the presence of thymoma (P < 0.01). In MG, the early stages of disease and thymoma-associated MG are responsive to treatment with CNIs.

AB - The objective was to assess which clinical factors of patients with myasthenia gravis (MG) are associated with responsiveness to calcineurin inhibitors (CNIs, cyclosporine and tacrolimus). We retrospectively analyzed the 6-month effects of CNIs in 62 MG patients. We excluded the influence of other immune treatments and determined factors associated with response to CNIs. The frequency of patients who achieved neither a ≥3-point reduction in quantitative MG score nor a ≥25% reduction in daily dose of prednisolone (poor responders) reached 35.5% (22/62) and 64.5% (40/62), respectively, compared with patients who achieved at least one of these improvements (responders). Neither dose nor blood concentration of CNIs differed between groups. Multivariate logistic regression analysis revealed time since onset of disease [odds ratio (OR) = 0.85, P = 0.005] and presence of thymoma (OR = 5.56, P = 0.05) as clinical factors that predict response to CNIs. As for MG-related autoantibody status, an autoantibody against a voltage-gated potassium channel, Kv1.4, was associated with response (OR = 9.01, P = 0.04) and showed a correlation with the presence of thymoma (P < 0.01). In MG, the early stages of disease and thymoma-associated MG are responsive to treatment with CNIs.

KW - Calcineurin inhibitors

KW - Logistic regression analysis

KW - Myasthenia gravis

KW - Odds ratio

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=76649084529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649084529&partnerID=8YFLogxK

U2 - 10.1002/mus.21462

DO - 10.1002/mus.21462

M3 - Article

C2 - 19816912

AN - SCOPUS:76649084529

VL - 41

SP - 212

EP - 218

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 2

ER -